NEW YORK, June 30, 2014 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the company will be presenting its lead drug development program during both the 9th Federation of European Neuroscience Societies (FENS) Forum of Neuroscience to be held July 5 9, 2014, in Milan, Italy and at the Alzheimer's Association International Conference® (AAIC) to be held July 12 17, 2014 in Copenhagen, Denmark.
The posters will highlight recent cell and animal studies showing that a compound selected by Oligomerix's proprietary technology platform can reduce pathological tau aggregates. These findings, which showed that the small molecules selected inhibited tau aggregation in mice, validate the Company's approach for drug development. Oligomerix welcomes these opportunities to meet with pharmaceutical companies to advance its goal of forming strategic partnerships.
9th FENS Forum of Neuroscience: Sunday, July 6, 2014:
Alzheimer's disease drug development targeting tau oligomer formation
Giulia Papiani, Patricia Lopez, James Hendrix, Pavan Krishnamurthy, Daisy Romero, Eliot Davidowitz, & James Moe
Exhibition Hall: MioCo Conference Center (12:15 PM 1:15 PM UTC)
AAIC 2014: Wednesday, July 16, 2014:
Drug development of inhibitors of tau oligomer formation for Alzheimer's disease and tauopathies
James Moe, Pavan Krishnamurthy, Patricia Lopez, Giulia Papiani, Daisy Romero, James Hendrix, & Eliot Davidowitz
Bella Center A/S, Center Blvd. 5, DK-2300 Copenhagen S (11:45 AM - 2:15 PM UTC)
Oligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. Founded in 2006, the Company is headquartered in Valhalla, NY and is carrying out its in vivo studies at New York Medical College. The Company is seeking strategic partners to help accelerate these exciting programs. For more information, visit www.oligomerix.com.
Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.
SOURCE Oligomerix, Inc.